[{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0.02,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vision Center Network of America","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vision Center Network of America","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Vision Center Network of America"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vantage Outsourcing","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vantage Outsourcing","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Vantage Outsourcing"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"intravitreal implant","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen and Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen and Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Cowen and Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"TYK","graph1":"Ophthalmology","graph2":"Phase I","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"TYK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"RLYB114","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"EyePoint Pharmaceuticals \/ Rallybio"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Alimera Sciences"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"","graph1":null,"graph2":null,"graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":null,"companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"}]

Find Clinical Drug Pipeline Developments & Deals by EyePoint Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The intends to use the net proceeds from the offering to advance clinical development of Duravyu (Vorolanib) for wet age related macular degeneration (wet AMD) and diabetic macular edema.

                          Brand Name : Duravyu

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Duravyu delivers vorolanib, a selective TKI in a bioerodible insert using EyePoint’s Durasert E™ technology, under phase 2 development for treating non-proliferative diabetic retinopathy.

                          Brand Name : Duravyu

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 06, 2024

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : EYP-1901 delivers vorolanib, a tyrosine kinase inhibitor formulated in a bioerodible insert using EyePoint's Durasert E™ technology. It is in phase 2 trials for treating diabetic macular edema.

                          Brand Name : EYP-1901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 10, 2024

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macul...

                          Brand Name : EYP-1901

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 08, 2023

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : $230.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macul...

                          Brand Name : EYP-1901

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 05, 2023

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : $200.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macul...

                          Brand Name : EYP-1901

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 04, 2023

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : J.P. Morgan

                          Deal Size : $201.2 million

                          Deal Type : Public Offering

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : EYP-1901 (vorolanib) is being developed as a sustained delivery treatment for wet age-related macular degeneration combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology (Durasert E™) with vorolanib, a tyrosine kin...

                          Brand Name : EYP-1901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 11, 2023

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior ...

                          Brand Name : Yutiq

                          Molecule Type : Small molecule

                          Upfront Cash : $75.0 million

                          May 18, 2023

                          Lead Product(s) : Fluocinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Alimera Sciences

                          Deal Size : $82.5 million

                          Deal Type : Divestment

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : EYP-1901 (vorolanib) is being developed as an investigational sustained delivery, for maintenance treatment of wet AMD combining a bioerodible formulation of Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.

                          Brand Name : EYP-1901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 27, 2023

                          Lead Product(s) : Vorolanib

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to po...

                          Brand Name : RLYB114

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          February 27, 2023

                          Lead Product(s) : RLYB114

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Rallybio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank